stockrow
Friday 6 November 2026
Export CGON’s income statement to Excel — free account
CG Oncology, Inc.
CGON Healthcare Biotechnology
CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024.
- Revenue
- −3.72%
- EPS
- −12.3%
- Free cash flow
- −25.2%
- Total debt
- 0.00%
Quarter to September 2026, against a year earlier
76.08
11.28
+17.41%
Follow CGON
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 6 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
— | 3 | — | — |
| (21.67%) | (20.79%) | (26.41%) | (28.29%) | ||
| (20.82%) | (20.04%) | (25.11%) | (26.73%) | ||
ROIC |
(886.69%) | (724.76%) | (4,111.64%) | (1,740.24%) | |
Return on Tangible Assets |
(21.63%) | (17.26%) | (22.06%) | (24.32%) | |
Average Days of Receivables |
55.85 | 90.84 | 24.44 | 0.00 | |
Free Cash Flow per Share |
(1.71) | (1.90) | (2.03) | (2.13) | |
Free Cash Flow |
(132.48) | (160.43) | (179.34) | (189.17) | |
Capital Expenditures |
(0.13) | (0.42) | (0.88) | (1.89) | |
| Other line items | |||||
Cash ROIC |
(8.85%) | (7.39%) | (8.70%) | (9.56%) | |
Accounts Receivable Turnover |
6.12 | 6.32 | 12.72 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 1.16 | 0.00 | |
Inventory Turnover |
— | — | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 402.75 | 0.00 | |
Days of Inventory on Hand |
0.00 | 0.00 | 31.74 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2,594.33% | 2,594.26% | 2,508.51% | 2,717.60% | |
Selling, General and Administrative Expense of Revenue |
1,635.36% | 1,552.16% | 1,462.48% | 1,471.16% | |
Share Based Compensation of Revenue |
593.33% | 546.54% | 567.21% | 591.16% | |
Operating CF/Net income |
0.82 | 0.86 | 0.80 | 0.79 | |
Depreciation/Fixed assets |
0.03 | 0.21 | 0.13 | 0.00 | |
Capex/Depreciation |
(0.31) | (0.13) | (0.45) | 0.00 | |
Revenue per Share |
0.06 | 0.06 | 0.07 | 0.07 | |
Operating CF per Share |
(1.71) | (1.89) | (2.02) | (2.11) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.02) | |
Capex to Sales |
0.03 | 0.08 | 0.14 | 0.31 |
Columns are period end dates · fundamentals updated 6 Nov 2026